PTAB Litigation Blog
  • Home
  • Cookie Policy
  • About
  • Advanced Topics
  • Contributors
  • Contacts
  • Design Patents
  • Discovery
  • District Court
  • Joinder
Select Page
PTAB Upholds Sloan Kettering’s Cancer Immunotherapy Patent

PTAB Upholds Sloan Kettering’s Cancer Immunotherapy Patent

by Cary Miller | Jan 26, 2017 | Final Written Decisions

By Galina Steinberg-Tatman, Ph.D. and Cary Miller, Ph.D. On December 16, 2016, the PTAB issued a final written decision in case IPR2015-01719, upholding all the claims of U.S. Patent 7,446,190, owned by Sloan Kettering Institute for Cancer Research (“Sloan”) and...
PTAB Institutes IPR Proceedings Against Mayne Pharma’s Antifungal Formulation Patent

PTAB Institutes IPR Proceedings Against Mayne Pharma’s Antifungal Formulation Patent

by Cary Miller | Jan 6, 2017 | Pharmaceutical, Trial Institution

By Unmesh Shah, Ph.D. and Cary Miller, Ph.D. The PTAB instituted an IPR on claims of Mayne Pharma International Pty Ltd.’s (“Mayne”) U.S. Patent No. 6,881,745 B2 covering formulations of azole antifungals in IPR2016-01186.  In response to Merck Sharp & Dohme...
Next Entries »

About this blog

Categories

  • 325(d) issues
  • Amendment Practice
  • CBMs
  • Claim Construction
  • Design Patents
  • Discovery
  • District Court
  • Estoppel
  • Evidentiary Issues
  • Expert Witnesses
  • Federal Circuit
  • Federal Circuit Appeal
  • Final Written Decisions
  • Joinder
  • Motions Practice
  • Other News
  • Patent Eligible Subject Matter
  • Petitions
  • PGR
  • Pharmaceutical
  • Preliminary Responses
  • Prior Art Issues
  • PTAB News
  • PTAB Trial Basics
  • Real Party in Interest
  • Request for Reconsideration
  • Standing
  • Stay
  • Time Limits
  • Trial Institution
  • Uncategorized

Archives

Links

www.jonesday.com

About Jones Day's Intellectual Property Practice

Subscribe to Jones Day publications

    • Privacy
    • X
    • RSS

    The opinions expressed are those of the authors and do not necessarily reflect the views of Jones Day or its clients. The posts and information provided are for general information purposes and are not intended to be and should not be taken as legal advice.